Skip to main content
CADL
NASDAQ Life Sciences

Candel's Prostate Cancer Therapy Shows Durable Immune Remodeling Two Years Post-Treatment

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.96
Mkt Cap
$832.522M
52W Low
$4.35
52W High
$14
52W Position info
152% above low
Off High info
22% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CADL has more than doubled off its 52-week low of $4.35.

Summary

Candel presented new biomarker data at ASTRO 2026 showing aglatimagene besadenovec plus radiation significantly increased intratumoral lymphocyte infiltration and remodeled the tumor microenvironment compared to placebo in intermediate-risk localized prostate cancer, with effects persisting more than two years after treatment and durable local and systemic immune activation. The analysis of 622 pre-treatment and 427 post-treatment biopsies found significantly greater lymphocyte-tumor engagement in residual tumors (p=0.003). A Phase 3 subgroup showed a 41% lower risk of recurrence or death. This mechanistic evidence supports the previously reported clinical benefit of improved disease-free survival and pathologic response, strengthening the case for the planned BLA submission. The company's cash runway extends into Q1 2028, providing ample time for regulatory filing and potential commercialization.

At the time of this announcement, CADL was trading at $10.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $832.5M. The 52-week trading range was $4.35 to $14.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $6.15 info
Change: +$1.04 (+20%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.15 info
Change: -$2.24 (-27%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.15 info
Change: -$2.24 (-27%) info
Market Cap: $486.365M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $6.15 info
Change: -$4.25 (-41%) info
Market Cap: $486.365M info
CADL
Sep 09, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.14
Real-time Price: $6.15 info
Change: -$5.99 (-49%) info
Market Cap: $486.365M info